Last reviewed 2026-04-20 · How we verify

Bucolom (BUCOLOME)

Phase 2 active Small molecule

Bucolom (generic name: BUCOLOME) is a bucolome drug. It is currently in Phase 2 development.

Bucolome is thought to work by interacting with a specific cellular pathway to produce a therapeutic effect.

Bucolome, a small molecule drug in the bucolome class, is a compound of unknown origin and current ownership. Its target and exact mechanism of action are also unknown. Bucolome's commercial status, including FDA approval and patent status, is unclear. Further research is needed to determine its approved indications, half-life, bioavailability, and generic manufacturers. As a result, key safety considerations and potential side effects are currently unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BUCOLOME
Drug class	bucolome
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells have a specific 'switch' that controls a certain process. Bucolome is believed to flip this switch, either turning it on or off, to help treat a particular condition. However, the exact details of how it interacts with this switch are still not fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bucolom CI brief — competitive landscape report
Bucolom updates RSS · CI watch RSS

Frequently asked questions about Bucolom

What is Bucolom?

Bucolom (BUCOLOME) is a bucolome drug.

How does Bucolom work?

Bucolome is thought to work by interacting with a specific cellular pathway to produce a therapeutic effect.

What is the generic name of Bucolom?

BUCOLOME is the generic (nonproprietary) name of Bucolom.

What drug class is Bucolom in?

Bucolom belongs to the bucolome class. See all bucolome drugs at /class/bucolome.

What development phase is Bucolom in?

Bucolom is in Phase 2.

Drug class: All bucolome drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing